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Abstract
Immunocamouflaged red blood cells (RBC) are produced by cell surface derivatization with methoxypolyethylene glycol
(mPEG). These immunologically attenuated cells may reduce the risk of allosensitization in chronically transfused patients.
To characterize the effects of differing linker chemistries and polymer lengths, RBC were modified with cyanuric chloride
activated mPEG (C-mPEG 5 kDa), benzotriazole carbonate methoxyPEG (BTC-mPEG; 5 or 20 kDa) or N-
hydroxysuccinimidyl ester of mPEG propionic acid (SPA-mPEG; 2, 5 or 20 kDa). Biophysical methods including particle
electrophoresis and aqueous two-phase polymer partitioning were employed to compare the PEG derivatives. While C-
mPEG was faster reacting, both BTC-mPEG and SPA-mPEG gave comparable findings after 1 h. Both PEG surface
density and molecular mass had a large effect on RBC surface properties. Proportional changes in electrophoretic mobility
and preferential phase partitioning were achieved by increasing either the quantity of surface PEG or the PEG molecular
mass. In addition, two-phase partitioning may provide a means for efficiently removing unmodified or lightly modified
(hence potentially immunogenic) RBC in the clinical setting. Furthermore, mPEG modification significantly inhibits cell^
cell interaction as evidenced by loss of Rouleaux formation and, consequently, sedimentation rate. Importantly, BTC-
mPEG 20 kDa RBC showed normal in vivo survival in mice at immunoprotective concentrations (up to 2 mM). ß 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
Methoxypolyethylene glycol (mPEG) is a neutral,
non-toxic polymer that has been covalently grafted
to proteins, biomaterials and cell surfaces as a means
of improving biocompatibility and reducing immu-
nological recognition. Examples of PEG-modi¢ed
agents include therapeutic proteins such as interleu-
kin 2 for anti-tumor e¡ects [1], streptokinase for
anti-thrombosis [2], liposomes for enhanced drug
and gene delivery [3] and, most recently, mPEG-de-
rivatized erythrocytes and lymphocytes [4^6].
mPEG-erythrocytes have been previously charac-
terized and were found to be morphologically and
functionally normal and, at immunoprotective levels,
to have normal in vivo survival in mouse models.
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More importantly, mPEG modi¢cation signi¢cantly
reduced the antigenicity of human red blood cells
(RBC) with respect to non-ABO blood group anti-
gens and dramatically diminished the immunogenic-
ity of allogeneic and even xenogeneic RBC in mouse
models [4,5]. As a consequence of this immunocam-
ou£age, mPEG-modi¢ed RBC may signi¢cantly at-
tenuate the risk of alloimmunization for patients re-
quiring chronic RBC transfusions such as patients
with sickle cell anemia and thalassemias. This is par-
ticularly important since as many as 35% of individ-
uals with sickle cell disease or thalassemias exhibit
clinically signi¢cant alloimmunization to non-ABO
antigens [7,8]. In this clinical setting, the immuno-
camou£aged mPEG-RBC would be most bene¢cial
in providing a safe, functional transfusion product.
To date, the majority of studies on PEGylated
RBC have employed cyanuric chloride activated
mPEG (C-mPEG) with a molecular mass of 5 kDa.
However, because both the density of attached PEG
as well as the mPEG chain length have been hy-
pothesized to alter the e⁄cacy of the immunocamou-
£age [4,9], we have assessed alternative mPEG deriv-
atives of varying molecular mass. Like C-mPEG,
both mPEG-benzotriazolyl carbonate (BTC-mPEG;
5 and 20 kDa) and mPEG succinimidyl propionate
(SPA-mPEG; 2, 5 and 20 kDa) react predominantly
with the O-amino groups of lysine residues and to a
lesser extent with amino-terminal groups in proteins.
However, unlike C-mPEG which introduces a tria-
zine ring between mPEG and the protein, BTC- and
SPA-mPEG attach mPEG to the target in the form
of a stable amide bond. Utilizing these di¡erent de-
rivatives of mPEG, the e⁄ciency of the PEG-RBC
linkage reaction and the e⁄cacy of immunocamou-
£age were assessed.
2. Materials and methods
2.1. Blood collection
Following informed consent, whole blood was
drawn from normal healthy volunteers into heparin
Vacutainer tubes. Erythrocytes were obtained by
washing three times with saline. Murine RBC were
collected in heparinized syringes from Balb/c mice
via cardiac bleed.
2.2. PEG derivatives
BTC-mPEG (5 and 20 kDa) and N-hydroxysucci-
nimidyl ester of mPEG propionic acid (SPA-mPEG;
2 and 20 kDa) were obtained from Shearwater Poly-
mers (Huntsville, AL, USA). SPA-mPEG 5 kDa was
purchased from Fluka Chemie (Sigma-Aldrich, St.
Louis, MO, USA). Cyanuric chloride activated
mPEG (C-mPEG; 5 kDa) was purchased from Sig-
ma. Bifunctional PEG derivatives, polyethylene gly-
col-bis-benzotriazolyl carbonate (BTC-PEG-BTC)
and the succinimidyl ester of polyethylene glycol-
bis-propionic acid (SPA-PEG-SPA) (PEG of 3.4
kDa), were obtained from Shearwater Polymers. De-
rivatives were used without further puri¢cation or
purity assessment. Derivatives from Shearwater
were s 95% pure. C-mPEG had 6 1% free cyanuric
chloride present.
2.3. PEG derivatization
Erythrocytes were modi¢ed either as whole blood
or as washed cells at a 12% or a 20% hematocrit as
previously described [4,10]. Brie£y, stock solutions of
PEG derivatives were made in 50 mM dibasic potas-
sium phosphate, 105 mM NaCl, pH 8.0 (PEG bu¡-
er). Overall mPEG concentrations ranged from 0 mM
to 7.5 mmol/l. Derivatization reactions were carried
out at room temperature for either 30 min or 1 h
according to the reactivity of the derivative. Modi¢ed
RBC were then washed three times with saline. Con-
trol groups consisted of both untreated saline washed
RBC and RBC incubated in mPEG-free PEG bu¡er
(0 mM mPEG-RBC).
2.4. Anti-A antibody-mediated RBC agglutination
This assay was used to assess the ability of at-
tached mPEG to inhibit anti-A antibody-mediated
agglutination. Brie£y, 450 Wl of control or pegylated
RBC (blood type A) suspensions (6% hematocrit in
isotonic saline) were placed in an aggregometer
cuvette at 37‡C, with stirring, and 20 Wl of anti-A
typing serum (or pooled human antiserum) was
added. RBC aggregation was then followed over
time using a platelet aggregometer as previously de-
scribed [4].
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2.5. Cell^cell interaction
In vitro and in vivo, RBC self-associate giving rise
to RBC ‘stacks’ (Rouleaux formation). In turn, this
Rouleaux formation underlies the sedimentation rate
used clinically. To assess this natural cell^cell inter-
action, sedimentation rate and Rouleaux formation
were measured for control and PEGylated RBC. For
analysis of sedimentation rate, control and mPEG-
RBC were suspended to a 40% hematocrit in autol-
ogous plasma and loaded into erythrocyte sedimen-
tation tubes (Winpette, Fisher Scienti¢c, Pittsburgh,
PA, USA). RBC sedimentation rate was then moni-
tored over a 5 h period. Simultaneously, aliquots
of the control and mPEG-derivatized RBC were
mixed with equal amounts of either autologous
plasma or a 1% saline-bu¡ered dextran solution
(dextran molecular mass V500 kDa, from Pharma-
cia, Uppsala, Sweden) (to induce Rouleaux forma-
tion) and examined microscopically for Rouleaux
formation.
2.6. In vivo survival of mPEG-modi¢ed RBC
To evaluate the e¡ects of the various mPEG de-
rivatives in vivo, RBC survival studies were per-
formed in Balb/c mice. RBC were collected from
donor mice via cardiac bleed and derivatized with
BTC-mPEG (20 kDa) as previously described [4,5].
The concentration of mPEG used for the in vivo
studies ranged from 0 to 2 mmol/l since murine
RBC are physically smaller (i.e. have fewer surface
binding sites for mPEG) and more fragile than hu-
man RBC. Murine RBC were labeled using the £uo-
rescent, membrane anchored marker PKH-26 (Sig-
ma). Blood samples from recipient mice were
followed until the labeled RBC were cleared from
circulation (approx. 40^50 days for unmodi¢ed syn-
geneic cells). Survival of £uorescently labeled mPEG-
treated and control RBC was monitored by analyz-
ing the percentage of £uorescently labeled RBC by
£ow cytometry. A minimum of ¢ve mice were used
for each mPEG concentration tested.
2.7. Biophysical determinations
To directly measure the e¡ects of linker chemistry
and polymer size, biophysical comparisons of the
control and mPEG-derivatized RBC were done via
partitioning in an aqueous two-phase polymer sys-
tem and particle electrophoresis. These techniques
have been used previously to monitor the consequen-
ces of PEG derivatization of proteins and the incor-
poration of PEG into liposomes [11^13]. Similarly,
these techniques have also been extensively used to
study erythrocyte surface properties [14,15]. Parti-
tioning in an aqueous two-phase polymer system
(which forms due to the immiscibility of the two
polymers: PEG and dextran) exploits the a⁄nity of
PEG-RBC for the PEG-rich upper phase. Unmodi-
¢ed as well as poorly derivatized RBC remain at the
interface or within the dextran layer. Particle electro-
phoresis measures the mobility of particles (e.g.
RBC) in an applied electric ¢eld. PEG-mediated
changes to the RBC surface are detected as a reduc-
tion in electrophoretic mobility due to the camou-
£age of RBC surface charge and the increased drag
force of the polymer itself.
2.8. Partitioning
Partitioning of control and PEG-modi¢ed RBC
was carried out in an aqueous two-phase system con-
sisting of PEG8000 (Sigma) and dextran T500 (mo-
lecular mass V500 kDa; Pharmacia). The two-phase
system denoted (5,4) was prepared as described pre-
viously [16,17] and consisted of 5% (w/w) dextran,
4% (w/w) PEG, 0.15 M NaCl, 6.84 mM Na2HPO4,
and 3.16 mM NaH2PO4 (pH 7.4). PEG and dextran
stock solution concentrations were determined by re-
fractive index measurements. Phase systems were
made up in 50 ml polypropylene tubes and allowed
to equilibrate overnight at room temperature. The
upper (PEG-rich) phase was drawn o¡ into a sepa-
rate tube and the lower (dextran-rich) phase was ob-
tained by puncturing the tube to collect the solution.
Phase systems were used within 3 days. Control and
PEG-RBC were labeled with 51Cr to allow for quan-
titation. The partitioning experiment was performed
in duplicate and consisted of the addition of 12 Wl
(load) of 51Cr-RBC (3.7U108/ml) to 0.75 ml each of
the upper and lower phases. Tubes were inverted 20
times and the phases were allowed to equilibrate and
separate at room temperature for 20 min. Aliquots
(350 Wl) from both phases were removed for Q-count-
ing. Results were expressed as the percentage of 51Cr-
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RBC in the upper phase relative to the total 51Cr-
labeled cells added to the system.
2.9. Particle electrophoresis
Mobility measurements for control and PEG-RBC
were made using the Rank Mark I electrophoresis
apparatus equipped with a horizontal microscope
with a water immersion lens [13,18]. Ten di¡erent
RBC were chosen randomly and were timed to de-
termine their velocity in the electric ¢eld. The electro-
phoretic mobility was determined as: mobility = ve-
locity of the particle (Wm/s)/electric ¢eld strength (E)
in V/cm, where E = (voltage/distance between the
electrodes).
3. Results
As previously reported, at immunoprotective levels
of derivatization, all of the monofunctional mPEG
moieties yielded morphologically normal RBC as as-
sessed by both microscopic and Coulter counter
analysis (data not shown; [4,5,19]). This ¢nding
was observed following mPEG derivatization of
both washed RBC and whole blood RBC. Only at
relatively high concentrations (s 2 mmol/l) of deri-
vatization with BTC-mPEG 20 kDa did the cells ap-
pear slightly crenated. In contrast, the bifunctional
derivatives proved to be less useful for our purposes
since signi¢cant, spontaneous, aggregation of the
RBC resulted due to cross-linking of individual
RBC.
Initial studies examined the di¡erential e¡ects of
modifying whole blood versus washed RBC. Not
surprisingly, since whole blood contains large
amounts of competing derivatization substrates (lym-
phocytes, plasma proteins, and platelets), derivatiza-
tion was more e⁄cient using washed RBC versus
whole blood at equimolar C-mPEG concentrations.
As shown in Fig. 1A, type A RBC agglutination was
inhibited to a greater extent following derivatization
of washed RBC as compared with derivatized whole
blood.
The direct relationship between the RBC:mPEG
derivative ratio, the e⁄cacy of linker chemistry, the
extent of cell modi¢cation, and the e¡ect of polymer
size was evident following two-phase partitioning.
Following extensive studies, a (5,4) (dextran, PEG)
system was found to be ideal for assessing and com-
Fig. 1. Greater mPEG attachment levels are achieved by modifying washed erythrocytes compared to whole blood. Erythrocytes were
modi¢ed with C-mPEG 5 kDa in whole blood (WB) or as washed cells (at either 20% or 12% hematocrit) for 30 min at room temper-
ature, pH 8.0. Concentrations of C-mPEG refer to the amount of C-mPEG reacted with RBC (not the amount attached). (A) Aggre-
gation of A-RBC in the presence of anti-A antisera illustrated the extent of mPEG modi¢cation obtained. As mPEG modi¢cation in-
creased, the amount of aggregation decreased since attached mPEG inhibits cell^cell interactions. Shown is a representative
experiment from three independent assays. (B) Di¡erent mPEG modi¢cation levels were also evident by partitioning in aqueous two-
phase systems. As the amount of attached mPEG increased, the percent of RBC partitioning in the upper, PEG-rich phase also in-
creased. Symbols show the mean data for three experiments, each done in duplicate þ 1 S.D.
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paring changes in RBC membrane derivatization. In
this two-phase system, only about 1% of unmodi¢ed
RBC partition to the upper PEG-rich phase while
V65% remain at the PEG^dextran interface and
34% are in the dextran-rich phase. As expected, the
transition of RBC from the interface/dextran layer to
the PEG-rich upper phase was a function of mPEG
derivative concentration, protein concentration
(washed RBC versus whole blood), and cell number
(hematocrit) (Fig. 1B). While 77% of modi¢ed
washed RBC (12% hematocrit) partitioned into the
upper PEG phase following derivatization with 1.2
mmol/l, only 19% of RBC from whole blood were
observed in the PEG-rich layer. Indicative of the
relationship between mPEG derivative concentration
per RBC, modi¢cation of higher hematocrits of
washed RBC yielded progressively lowered partition-
ing into the PEG-rich layer. For example, derivatiza-
tion of a 20% hematocrit with 1.2 mmol/l C-mPEG
resulted in 38% of the RBC partitioning to the upper
PEG phase.
The two-phase partitioning system was also em-
ployed to assess whether any di¡erences in reaction
rates and overall membrane derivatization existed
between the three chemical linker agents. As noted
in Fig. 2A, C-mPEG more rapidly derivatized RBC
when compared to either the BTC- or SPA-mPEGs.
To obtain an upper PEG phase partition of 50%
after 30 min of reaction time, less C-mPEG 5 kDa
(1.2 mM) was required compared with BTC- or SPA-
mPEG 5 kDa (1.8 mM). After a 1 h reaction time,
less than 0.9 mM C-mPEG was required compared
to 1.2 mM BTC- or SPA-mPEG 5 kDa to give an
upper PEG phase partition of 50% (Fig. 2B). The
greater reactivity of C-mPEG was also demonstrated
via microaggregometry in that less C-mPEG (e.g. 0.6
mmol/l C-mPEG 5 kDa versus 1.2 mmol/l BTC- or
SPA-mPEG 5 kDa) was required to achieve signi¢-
cant (s 50%) inhibition of antiserum-mediated ag-
glutination (data not shown). However, while BTC
and SPA-mPEGs react more slowly with RBC than
C-mPEG, equivalent partitioning was noted after 1 h
of derivatization (Fig. 2B).
In addition to PEG surface density, the molecular
mass of the mPEG derivative also had an enormous
e¡ect on RBC surface properties as determined by
both partitioning and particle electrophoresis (Figs. 3
and 4). Aqueous two-phase partitioning data con-
¢rmed the very strong mPEG derivative molecular
mass e¡ect (Fig. 3). To achieve V50% partitioning
into the upper phase, only 0.3^0.45 mM mPEG 20
kDa (BTC or SPA) was required compared to 1.2
mM mPEG 5 kDa derivatives or 2.5 mM SPA-
mPEG 2 kDa. To achieve over 80% partitioning
Fig. 2. The C-mPEG derivative reacts faster than BTC- or SPA-mPEG in grafting mPEG to the RBC membrane. RBC (washed and
at a 12% hematocrit) were modi¢ed with mPEG 5 kDa derivatives: C-mPEG, BTC- or SPA-mPEG for either 30 min (A) or for 1 h
(B) at room temperature, pH 8. Control and modi¢ed RBC were partitioned in the (5,4) aqueous two-phase system. Symbols show
the mean data for three experiments, each done in duplicate. Error bars are 1 S.D. Data for RBC modi¢ed with C-mPEG for 30 min
are included in panel B for ease of comparison.
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into the PEG phase, 0.6 mM SPA/BTC-mPEG 20
kDa or V2 mM SPA/BTC-mPEG 5 kDa or 5 mM
SPA-mPEG 2 kDa were required. Assessing the ef-
fect of molecular mass in terms of the total number
of ethoxy units, slightly more of the 20 kDa PEG
derivatives were required to achieve equivalent a⁄n-
ity partitioning. The ratio of ethoxy units required
for 50% a⁄nity partitioning was V(1:1.2:1.2^1.8)
for the PEG 2 kDa (n = 45):PEG 5 kDa
(n = 113):PEG 20 kDa (n = 454) respectively, where
n is the number of ethoxy units per molecule. To
achieve 80% a⁄nity partitioning, the ratio was
(1:1:1.2).
These partitioning ¢ndings are of importance since
a key clinical requirement for the use of PEGylated
RBC in the prevention of alloimmunization will be
Table 1
Separation of mPEG-modi¢ed erythrocytes from unmodi¢ed cells is e⁄ciently accomplished via two-phase partitioning
Cell types Mixture: percent mPEG-derivatized cells (mean þ S.D.)
10 30 50 70 90
C-mPEG 5 kDa 9.6 þ 1.9 (96 þ 19%) 29.7 þ 3.8 (99 þ 12%) 45.7 þ 2.6 (91 þ 5%) 65.1 þ 3.5 (93 þ 5%) 81.4 þ 2.8 (90 þ 3%)
BTC-mPEG 5 kDa 10.8 þ 1.3 (108 þ 13%) 29.1 þ 5.6 (97 þ 19%) 50.6 þ 5.2 (101 þ 10%) 63.7 þ 3.1 (91 þ 4%) 85.6 þ 6.7 (95 þ 7%)
SPA-mPEG 5 kDa 11.9 þ 2.6 (119 þ 26%) 30.1 þ 5.7 (100 þ 19%) 50.2 þ 7.8 (100 þ 16%) 70.0 þ 7.6 (100 þ 11%) 84.6 þ 6.1 (94 þ 7%)
BTC-mPEG 20 kDa 12.0 þ 2.4 (120 þ 24%) 31.2 þ 5.6 (104 þ 19%) 49.5 þ 8.2 (99 þ 16) 69.2 þ 5.6 (99 þ 8%) 84.3 þ 2.0 (94 þ 2%)
SPA-mPEG 20 kDa 9.7 þ 1.6 (97 þ 16%) 30.0 þ 6.1 (100 þ 20) 47.6 þ 7.3 (95 þ 14) 65.4 þ 3.9 (93 þ 6%) 84.7 þ 4.3 (94 þ 5%)
To determine the ability to separate mPEG-modi¢ed cells from unmodi¢ed control cells, cell mixing experiments were done. 51Cr-La-
beled PEGylated RBC (2.5 mM mPEG 5 kDa or 0.9 mM mPEG 20 kDa) were prepared and mixed at the indicated percentages with
51Cr-labeled unmodi¢ed control RBC. Cell mixtures were subjected to two-phase partitioning. The values shown represent the actual
percentage of RBC in the upper PEG-rich phase. Values in parentheses represent the percent theoretical maximum recovery of the
PEGylated 51Cr-RBC.
Fig. 3. E¡ect of linker chemistry and polymer size on aqueous
two-phase partitioning of mPEG-modi¢ed RBC. Shown is a
comparison of the phase partitioning of BTC-mPEG (5 and 20
kDa) and SPA-mPEG (2, 5 and 20 kDa). (A) RBC partitioning
into the PEG-rich phase increases in an mPEG dose-dependent
manner. Partitioning is further enhanced by increasing polymer
length (molecular mass). (B) Similar partitioning results were
obtained with the SPA derivatives. Again, note the dramatic
and signi¢cant e¡ect that polymer length has at equimolar con-
centrations of derivatization. RBC were derivatized as washed
cells at a 12% hematocrit for 1 h at room temperature. Symbols
show the mean data þ 1 S.D. for duplicate samples from three
independent experiments.
Fig. 4. Electrophoretic mobility is decreased consequent to im-
munocamou£age. Shown is a comparison of the electrophoretic
mobility of control and BTC-mPEG (A; 5 and 20 kDa) and
SPA-mPEG (B; 2, 5 and 20 kDa) derivatized human RBC.
RBC electrophoretic mobility is a function of the membrane
surface charge and the drag coe⁄cient of the RBC itself. Under
the conditions used, normal human RBC have a mobility of ap-
prox. 31.18 WmWcm/VWs. As shown, mPEG derivatization results
in the immunocamou£age of the inherent surface charge of the
RBC resulting in the loss of electrophoretic mobility. The e⁄-
cacy of the immunocamou£age is a function of polymer density
(mM) and polymer length (kDa). As the mPEG molecular mass
and derivatization concentrations increased, a greater shift in
mobility towards zero was observed. Complete neutralization of
the electrophoretic mobility is noted at very low derivatization
concentrations of the 20 kDa BTC- and SPA-mPEGs. RBC
were modi¢ed as washed cells at a 12% hematocrit for 1 h at
room temperature. The electrophoretic mobilities of control and
mPEG-modi¢ed cells were determined using measurements for
10 RBC per experiment. Symbols show the mean of two inde-
pendent experiments þ 1 S.D.
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the necessity of removing unmodi¢ed or insu⁄ciently
modi¢ed RBC. As demonstrated in Table 1, the two-
phase partitioning system is ideally suited for this
task as mixtures of mPEG-modi¢ed RBC and un-
modi¢ed RBC were successfully separated. Follow-
ing two-phase separation, approx. 90% of mPEG-
derivatized RBC were readily recovered from the
PEG-rich layer by removing the top phase, diluting
this phase in saline, then concentrating the RBC by
low speed centrifugation.
Particle electrophoresis data (Fig. 4) for mPEG-
RBC with varying mPEG chain sizes demonstrated
that mobility shifts were directly related to the poly-
mer molecular mass. While larger polymers yielded
larger shifts in RBC mobility towards zero, smaller
polymers yielded small mobility decrements (regard-
less of the linker used). For example, the loss of
approx. 50% of the inherent RBC mobility (i.e.
from 31.2 to 30.6 WmWcm/VWs) was achieved by ad-
dition of as little as 0.3 mM BTC-mPEG 20 kDa as
compared with V2 mM BTC-mPEG 5 kDa (Fig.
4A). Similarly, only 0.3 mM SPA-mPEG 20 kDa is
required versus 2.5 mM SPA-mPEG 5 kDa. Deriva-
tization of RBC with the short SPA-mPEG 2 kDa
derivative was insu⁄cient at the highest concentra-
tion tested to lower the mobility to 0.6 WmWcm/VWs
(Fig. 4B). Indeed, substantially higher numbers of
total ethoxy units were required for the PEG 5 kDa
derivatives ((2.1:1), SPA-PEG 5 kDa:SPA-PEG 20
kDa).
In addition to the monofunctional derivatives em-
ployed, bifunctional PEG derivatives were also inves-
tigated. Fig. 5 demonstrates that RBC surface mod-
i¢cation is readily achieved using the bifunctional
BTC-PEG 3.4 kDa-BTC and SPA-PEG 3.4 kDa-
SPA compounds. Electrophoretic mobility shifts for
RBC modi¢ed with these bifunctional derivatives
were, as might be expected, between those for the
monofunctional 5 kDa and 2 kDa SPA-mPEGs
(Figs. 5A and 4A). Whether RBC were modi¢ed
with BTC- or SPA-PEG bifunctional derivatives,
mobility pro¢les were comparable. Similarly, two-
phase partitioning patterns for the bifunctional
PEG 3.4 kDa-derivatized RBC were indistinguish-
able from one another (Fig. 5B). Unexpectedly, how-
ever, the bifunctional derivatives actually enhanced
antiserum-mediated aggregation (Fig. 5C). Due to
the presence of the two linker groups, a high degree
Fig. 5. Modi¢cation of RBC with bifunctional PEG derivatives adversely a¡ects the RBC. RBC (washed and at a 12% hematocrit)
were modi¢ed with the bifunctional BTC-PEG-BTC or SPA-PEG-SPA derivatives. In both cases the polymer size was 3.4 kDa. (A) As
expected by the polymer size, the shift in electrophoretic mobility of the bifunctional mPEG derivatives was intermediate between the
2 and 5 kDa SPA-mPEG. However, it was observed microscopically during these studies that a signi¢cant percentage of the cells
were aggregated together do to PEG cross-linking. (B) Grafting of the bifunctional PEG polymers to the RBC membrane resulted in
the expected partitioning of the modi¢ed RBC to the PEG-rich phase. (C) The e¡ect of RBC cross-linking and microaggregate forma-
tion due to the bifunctional derivatives was apparent in RBC aggregation studies. As shown, both the SPA-PEG-SPA and BTC-PEG-
BTC bifunctional derivatives (5 mM derivatization concentration) actually enhanced type A RBC aggregation in response to anti-A
serum. In contrast, the monofunctional BTC-mPEG (5 mM) completely inhibited antiserum-mediated agglutination under the same
conditions. Consequent to these studies, the use of these bifunctional derivatives was discontinued. Symbols for panels A and B show
the mean data for three experiments þ 1 S.D., each done in duplicate. Microaggregation data are representative of three independent
assays. Derivatized RBC shown were modi¢ed with 5.0 mM of the PEG derivative indicated.
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of RBC-RBC cross-linkage was noted. Indeed, mi-
croscopic analysis conducted during the particle elec-
trophoresis studies demonstrated numerous small ag-
gregates of RBC.
The e¡ect of linker chemistry and polymer size on
Rouleaux formation and sedimentation rate was also
assessed. Microscopic examination of the modi¢ed
RBC demonstrated that cell^cell interactions were
disrupted consequent to mPEG derivatization. This
is graphically observed via Rouleaux formation in
which RBC self-aggregate to form stacks of cells.
As shown in Fig. 6, normal, unmodi¢ed RBC read-
ily form Rouleaux structures in the presence of dex-
tran. In contrast, mPEG modi¢cation inhibits the
cell^cell interactions required for Rouleaux forma-
tion leading to the random distribution of cells in
the microscope ¢eld. Consequent to the loss of Rou-
leaux formation, erythrocyte sedimentation rate
(ESR) is signi¢cantly diminished in a dose-dependent
manner. As shown in Fig. 6A, C-mPEG 5 kDa sig-
ni¢cantly decreases the ESR as a function of mPEG
dose. The loss/delay in sedimentation rate is signi¢-
cant (P6 0.01) even at 0.6 mM of derivatization.
However, even at this low derivatization dosage,
self-association and sedimentation do occur with
Fig. 7. In vivo survival of mouse mPEG-modi¢ed RBC is nor-
mal at immunoprotective levels of derivatization (2 mM) with
BTC-mPEG 20 kDa. In vivo survival of mPEG-derivatized
mouse RBC is normal even after repeated infusions. Shown are
the clearance rates of transfused control and BTC-mPEG 20
kDa-modi¢ed mouse RBC. Survival was followed using a £uo-
rescent fatty acid label (PKH-26) as described in Section 2.
Each infusion approximated 8^10% of the total mouse RBC
mass (based on weight and calculated blood volume). Following
each RBC administration, cell clearance was allowed to proceed
until no detectable label remained (approx. 50 days). Each time
point represents the mean of a minimum of ¢ve Balb/c mice.
Murine RBC survival studies utilized both i.v. and i.p. transfu-
sion of the donor cells with no di¡erences in survival kinetics
noted between the two modes of administration.
Fig. 6. Increasing polymer size prevents RBC sedimentation and Rouleaux formation. In vitro (in the presence of dextran) and in
vivo, RBC self-associate giving rise to RBC ‘stacks’ (Rouleaux formation). In turn, the Rouleaux formation underlies RBC sedimenta-
tion. For analysis of sedimentation rate, control and mPEG-RBC (RBC modi¢ed as washed cells at a 12% hematocrit) were sus-
pended to a 40% hematocrit in autologous plasma and loaded into erythrocyte sedimentation tubes. RBC sedimentation rate was then
monitored over a 5 h period. Simultaneously, aliquots of the control and mPEG-derivatized RBC were mixed with equal amounts of
either autologous plasma or a 1% saline-bu¡ered dextran solution (to induce Rouleaux formation) and examined microscopically for
Rouleaux formation.
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time as noted by the di¡erence between 1 and 5 h of
sedimentation in the 0.6 mM-modi¢ed RBC. In con-
trast, subsequent to derivatization with BTC-mPEG
20 kDa, only a minor increase in sedimentation oc-
curs over 5 h of incubation (Fig. 6B). These latter
results clearly demonstrate the e⁄cient disruption of
cell^cell (Rouleaux) association by the larger poly-
mers.
Surprisingly, in vivo survival studies also demon-
strated that BTC-mPEG 20 kDa was vastly superior
to the lower molecular mass (5 kDa) C-mPEG de-
rivatives using the exact same modi¢cation condi-
tions. As previously reported by us [5], C-mPEG
5 kDa derivatization of murine RBC at concentra-
tions v0.6 mM gave rise to signi¢cantly shortened in
vivo survival. In part, the loss of viability resulted
from the inherently fragile nature of murine RBC.
However, modi¢cation of the linker chemistry as
well as the use of longer polymers results in signi¢-
cantly improved in vivo survival of murine RBC. As
Fig. 8. Immunocamou£age of membrane antigens is a function of linker chemistry, polymer size, and polymer surface density.
(A) Shown is a graphical representation of the RBC membrane and the topical distribution of the Rh (C/c), Kidd (Jka=b) and MNS
(S/s) blood group antigens. The PEG exclusion layer is the physical entity which gives rise to the immunocamou£age of the membrane
antigens. The e⁄cacy of the heavily hydrated, neutrally charged, exclusion layer is a function of the length and density of the highly
mobile PEG polymer which imparts a space ¢lling (i.e. steric hindrance) cloud around the cell. Indeed, the PEG exclusion layer acts
as a molecular size sieve allowing small molecules (e.g. O2 and glucose) and proteins to e⁄ciently cross while excluding larger proteins
(e.g. antibodies). Similarly, the obfuscation of the inherent surface charge (Fig. 4) of the cell membrane by the neutral PEG layer is
also of importance in preventing both antibody^antigen interaction and cell^cell interaction. Represented are the relative exclusion
layers of 2, 5 and 20 kDa polymers. (B) The Rh antigens are located close to the membrane surface, consequently even relatively
short polymers (e.g. 5 kDa) can e¡ectively camou£age these sites. Shown is the immunocamou£age of the Rhc antigen as re£ected by
the decrease in mean cell £uorescence. As noted, both 5 kDa polymers similarly camou£aged the Rhc antigen. While increased poly-
mer length (20 kDa) improved the immunocamou£age of the Rh antigens, the e¡ect was moderate. (C) In contrast to the Rh anti-
gens, polymer length was a critical determinant in the immunocamou£age of the MNS and Kidd blood group antigens. As demon-
strated, neither 5 kDa polymer resulted in the immunocamou£age of the Jkb antigen. In contrast, the 20 kDa polymer began to exert
an e⁄cient immunocamou£age of Jkb.
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shown in Fig. 7, in vivo survival studies using the 20
kDa BTC-mPEG resulted in normal survival kinetics
(i.e. V50 days) even at a derivatization concentra-
tion of 2 mM. Importantly, these in vivo data dem-
onstrate that normal survival of cells is readily
achievable at derivatization concentrations that im-
part an e¡ective immunocamou£age of human RBC.
Furthermore, as demonstrated by our previous stud-
ies, PEGylation of murine RBC also does not gen-
erate any neoantigens [4,20].
Finally, we investigated the e¡ects of membrane
topography on the e⁄cacy of mPEG-mediated im-
munocamou£age. Inhibition of antibody binding to
Rhc and JKb consequent to mPEG derivatization
was assessed via £ow cytometry. While Rhc resides
close to the lipid bilayer, JKb is present well above
the membrane (Fig. 8). For Rhc, inhibition of anti-
body binding was mPEG dose-dependent with in-
creasing chain length (molecular mass) having only
a small enhancing e¡ect (Fig. 8B). In contrast, for
antigenic determinants farther out from the lipid bi-
layer, the 5 kDa mPEGs were completely ine¡ective,
regardless of chain density. However, as demon-
strated with the 20 kDa BTC-mPEG, with increasing
chain length and density, increasing immunocamou-
£age was observed (Fig. 8C). These ¢ndings clearly
illustrate the importance of antigen topography on
the e⁄cacy of immunocamou£age and perhaps indi-
cate why the murine cells derivatized with 20 kDa
BTC-mPEG have improved survival when compared
to the 5 kDa derivatized cells.
4. Discussion
Characterizing, quantifying and controlling the
biophysical and immunological consequences of
mPEG derivatization of RBC are vital for the suc-
cessful application of this novel technology in trans-
fusion medicine. To this end, the biophysical and
biological e⁄cacy of three di¡erent chemical linkers
with di¡erent polymer lengths (molecular mass) was
assessed via particle electrophoresis, aqueous two-
phase partitioning, sedimentation rate and in vivo
survival.
The chemical linkers used to activate the mPEG
(C-, BTC-, and SPA-mPEG) for covalent binding of
the polymer to proteins all preferentially target the
O-amino group of exposed lysine residues on mem-
brane proteins. While sharing the same targets, BTC-
and SPA-mPEGs di¡er from C-mPEG in that they
attach mPEG directly to the lysine residue without
introducing a bulky linker moiety. Comparison of
the mPEG 5 kDa derivatives demonstrated that C-
mPEG reacted most rapidly but, given appropriate
derivatization time (1 h versus 30 min), SPA- and
BTC-mPEG-modi¢ed RBC exhibited similar bio-
physical (particle electrophoresis, phase partitioning)
and immunological (inhibition of Rouleaux forma-
tion and non-ABO antigen detection) characteristics
(Figs. 2^4, 6 and 8). Hence, any of these monofunc-
tional linkers could be suitable for RBC derivatiza-
tion in the clinical setting.
Other important ¢ndings relate to the e¡ects of
polymer size; i.e. size does matter. Larger polymers
were found to more e¡ectively camou£age RBC as
demonstrated by both biophysical and immunologi-
cal measurements. While both particle electrophore-
sis and partitioning results demonstrated that smaller
quantities of the larger PEG derivatives were re-
quired to exert signi¢cant PEG-speci¢c e¡ects, par-
ticle electrophoresis proved to be more sensitive to
PEG derivative molecular mass changes than parti-
tioning. For example, a 4-fold increase in mPEG
derivative molecular mass (from 5 kDa to 20 kDa)
resulted in the requirement of 7^8 times less mPEG
derivative to achieve a 50% shift in cell mobility. In
contrast, the same 4-fold increase in the polymer size
resulted in only a 3^4-fold decrease in the derivative
concentration required to achieve 80% partitioning
into the PEG-rich phase.
This heightened e¡ect of mPEG molecular mass
demonstrated by particle electrophoresis may also
be discussed as a function of the number of ethoxy
units. Less than half of the total ethoxy units were
required for mPEG 20 kDa derivatives compared to
mPEG 5 kDa derivatives to decrease the cell mobility
by 50%. The greater inhibition of cell mobility by the
large PEGs is likely due to the much greater drag
force contributed by the longer polymers. In con-
trast, in the a⁄nity partitioning system, slightly
more of the larger PEGs were required (beyond
that required to give an equivalent number of ethoxy
units). Since the a⁄nity partitioning of mPEG-RBC
into the PEG-rich phase is related to the number of
ethoxy units attached, these data may re£ect that
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fewer of the 20 kDa derivative molecules are at-
tached. This ¢nding was expected as the binding of
a few mPEG 20 kDa polymers is likely to sterically
inhibit the approach and binding of further mole-
cules over a much larger surface area of the cell. In
contrast, the smaller molecular mass mPEG deriva-
tives sterically inhibit over a much smaller membrane
surface area thus allowing for the approach and
binding of more polymers.
In contrast to the monofunctional mPEG deriva-
tives, bifunctional PEGs were not suitable for RBC-
PEGylation using current conditions. At the ratios
used for modifying RBC, the two bifunctional deriv-
atives, BTC-mPEG 3.4 kDa-BTC and SPA-mPEG
3.4 kDa-SPA, were found to cross-link RBC during
the derivatization procedure. This cross-linking e¡ec-
tively interfered with the ability of PEG to keep cells
apart from one another (which is the key to inhibit-
ing agglutination since the anti-A antibody still binds
the type A PEG-modi¢ed RBC [10]). Consequently,
when anti-A antibodies are added in the agglutina-
tion reaction, inhibition of the antibody-mediated
cell^cell interaction is not seen. Agglutination would
also be ampli¢ed due to the pre-existence of small
RBC aggregates. We hypothesize that, in some cir-
cumstances, these bifunctional PEG derivatives may
prove useful if RBC numbers are signi¢cantly re-
duced (i.e. diluted) to minimize cell^cell cross-link-
ing.
As predicted by these studies, the immunocamou-
£age of RBC membrane antigens is determined by
the number of grafted mPEG molecules, polymer
size (i.e. molecular mass), antigen density and anti-
gen topography (i.e. the relative height of the antigen
above the membrane surface). These ¢ndings are
graphically presented in Fig. 8. As demonstrated in
this ¢gure, antigenic and immunogenic epitopes such
as human RhC/c (as well as other Rh antigens; Fig.
8A,B) which are close to the membrane surface are
e¡ectively camou£aged by both short and long chain
polymers at low to medium levels of derivatization.
Hence, antigens such as RhC that statistically exhibit
an approx. 5% risk of alloimmunization after a single
transfusion, should show a dramatically decreased
risk following RBC PEGylation. In contrast, other
antigens such as the Kidd and MNS blood group
antigens that extend well above the membrane are
less e⁄ciently camou£aged by the short chain poly-
mers but can be e¡ectively hidden by the longer
chain polymers (Fig. 8A,C). To what extent RBC
PEGylation will attenuate alloimmunization to these
later antigens remains unclear. However, antigenic
recognition and immunogenicity are not the same.
Importantly with regard to this question, we have
previously demonstrated that antibody formation
(i.e. immunogenicity) in response to PEGylated allo-
geneic and xenogeneic RBC in mice is e¡ectively
blunted [19], suggesting that even epitopes far away
from the membrane are protected from immunologic
presentation consequent to membrane derivatization.
Of equal importance to the potential clinical appli-
cations of mPEG-RBC is the e¡ect of PEGylation on
cell^cell interactions. As described herein, Rouleaux
formation as well as antibody-mediated RBC^RBC
interactions were e¡ectively blocked by mPEG mod-
i¢cation. These ¢ndings may have implications with
regard to the vasoocclusive events characteristic of
sickle cell disease. In sickle cell disease, vasoocclusive
events are mediated by the enhanced viscosity and
aggregation of abnormal RBC in the small arterioles
and capillaries. However, as we have recently dem-
onstrated, PEG-RBC serve as e⁄cient chain breakers
during aggregation of unmodi¢ed RBC [19]. Hence,
consequent to the PEG exclusion volume, RBC re-
tain better £ow characteristics in the arterioles, resist
agglutination, and do not adhere to endothelial sur-
faces. Indeed, an excellent study by Armstrong et al.
[21] clearly demonstrated that mPEG modi¢cation
reduces low shear viscosity. This loss of viscosity is
clearly due to impaired cell^cell interaction as readily
evidenced by the loss of Rouleaux formation and
decreased sedimentation rate. Finally, the inhibition
of cell^cell interactions (e.g. monocyte^RBC or anti-
gen presenting cell^T lymphocyte) likely underlies
the blunted immune response to mPEG-modi¢ed
cells since immunorecognition requires both cell^
cell and cell^antibody interactions for the induction
of an e⁄cient immunological response [4,6].
Finally, a critically important step in the potential
clinical utilization of the PEG-RBC is the separation
of modi¢ed (i.e. non-immunogenic) from unmodi-
¢ed/undermodi¢ed (i.e. immunogenic) cells. As dem-
onstrated in this study, the biophysical changes aris-
ing from membrane derivatization allow for the
rapid and e⁄cient processing and recovery of immu-
nocamou£aged (PEG-modi¢ed) RBC. For example,
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mixtures of strongly PEGylated cells (2.5 mM PEG
5 kDa or 0.9 mM PEG 20 kDa derivatives) and
unmodi¢ed cells were easily and e⁄ciently separated
by aqueous two-phase partitioning. mPEG-RBC in
the upper, PEG-rich phase were then recovered by
diluting the PEG phase in saline (to decrease the
viscosity) followed by low speed centrifugation. Im-
portantly, this simple method for separating and re-
covering PEG-modi¢ed RBC can be readily scaled
up to manufacturing proportions as was previously
done for enzymes (e.g. phosphorylase, several dehy-
drogenases) puri¢ed from microorganisms [22].
In sum, multiple linker molecules (cyanuric chlo-
ride, BTC, and SPA) were all e⁄cient at derivatizing
RBC membranes with mPEG. No signi¢cant di¡er-
ences, other than rate of reaction, were observed be-
tween the linker moieties when comparable polymer
sizes were assessed via particle electrophoresis, two-
phase partitioning, and immunological analyses.
Both polymer surface density and polymer size sig-
ni¢cantly in£uenced the biophysical (electrophoretic
mobility, phase partitioning, and cell^cell interac-
tion) and immunological characteristics of modi¢ed
RBC. While it was anticipated that larger polymers
would achieve better immunocamou£age, we were
pleasantly surprised that the larger polymers also
exhibited improved in vivo viability at equimolar
concentration. Furthermore, these data suggest that
the derivatization and puri¢cation of mPEG-RBC
can be e⁄ciently and economically done in the Blood
Bank setting. Clinical usage of these modi¢ed cells
may have tremendous therapeutic advantage in man-
aging sickle cell disease which is aggravated by sig-
ni¢cant disparities in non-ABO antigens and vaso-
occlusive events arising from enhanced cell^cell
interactions.
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